Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

wIPV+bOPV

Phase 3Biologic

BBeijing Minhai Biotechnology Co., Ltd

wIPV+bOPV is one of 11 biologic programs targeting Poliomyelitis. It is currently in Phase 3.

1

Indications

1

Total Trials

0

Active Trials

10

Competitors

Pipeline

Status by Indication[3][1]

Indication

PoliomyelitisActive, not recruiting

PoliomyelitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

30 competitors in Poliomyelitis

#DrugCompanyPhaseTrials

Comparator: Pbo

Rotateq

Hepatitis B Vaccine

Inactivated Rabies Virus Vaccine

Sipv

Sinovac Biotech Co., Ltd

Concomitant Administration

wIPV+bOPV

BBeijing Minhai Biotechnology Co., Ltd

Oral NVB Metronomic

Verazinc

FFakultas Kedokteran Universitas Indonesia

Poliorix.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Poliomyelitis1 trial

A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants

Completed·BBeijing Minhai Biotechnology Co., Ltd·Phase 3·NCT06752174·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for wIPV+bOPV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — wIPV+bOPV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for wIPV+bOPV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Minhai Biotechnology Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: BBeijing Minhai Biotechnology Co., Ltd

Related News